Logo for Caribou Biosciences Inc

Caribou Biosciences Investor Relations Material

Latest events

Logo for Caribou Biosciences

Q2 2024

6 Aug, 2024
Logo for Caribou Biosciences

Corporate Presentation

4 Jun, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Caribou Biosciences Inc

Access all reports
Caribou Biosciences Inc. is a clinical-stage biopharmaceutical company at the forefront of genome editing technology. It focuses on developing genome-edited allogeneic cell therapies for the treatment of cancer and other devastating diseases. The company utilizes CRISPR-Cas9 technology to create precise, directed changes in the DNA of living cells, aiming to develop innovative therapies that can address unmet medical needs. Caribou's leading product candidates include allogeneic chimeric antigen receptor T (CAR-T) cell therapies for hematologic malignancies and solid tumors. This approach allows for the development of therapies that are not patient-specific but can be used as "off-the-shelf" treatments, potentially reducing time and cost compared to traditional autologous CAR-T therapies. The company is headquartered in Berkeley, CA, and its shares are listed on the NASDAQ.